GlassScriptPhysician profile
Scott D Taylor
NPI 1477517878
$11,952.68
in general payments reported to CMS, 2019-2025
34 companies · $1,843 in 2025
The $1,843 reported for 2025 was more than what 90% of Medical providers received nationally (typical 2025 total: $213).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $2,517 · 2022: $2,213 · 2023: $2,432 · 2024: $2,947 · 2025: $1,843.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,222.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,222.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $1,440.62 | 2021-2025 | |
| Glaxosmithkline, LLC. | $1,287.40 | 2021-2025 | Trelegy Ellipta, Arexvy, Shingrix |
| Lilly USA, LLC | $1,208.04 | 2021-2025 | Mounjaro, Jardiance, Zepbound |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $1,140.60 | 2021-2025 | Xifaxan |
| Novo Nordisk INC | $986.38 | 2021-2025 | Ozempic, Rybelsus, Wegovy |
| Astrazeneca Pharmaceuticals LP | $930.70 | 2021-2025 | Breztri, Airsupra, Farxiga |
| Boehringer Ingelheim Pharmaceuticals, INC. | $674.31 | 2021-2025 | Jardiance, Synjardy, Tradjenta |
| Pfizer INC. | $540.69 | 2021-2025 | |
| Kowa Pharmaceuticals America, INC. | $392.33 | 2021-2023 | Livalo, Seglentis |
| Janssen Pharmaceuticals, INC | $280.18 | 2021-2023 | Xarelto |
| Amgen INC. | $276.31 | 2022-2025 | Repatha, Otezla, Otezla |
| Exact Sciences Corporation | $273.34 | 2023-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Takeda Pharmaceuticals U.S.A., INC. | $270.43 | 2021-2025 | Trintellix |
| Amarin Pharma, INC. | $252.81 | 2021 | |
| Abbott Laboratories | $197.30 | 2022-2025 | Freestyle Libre 3, Freestyle Libre 2 |
Show all 34 companies
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Scott Taylor listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.